Dr Dalmas received her doctoral, Masters and Bachelor of Science degrees, in Pharmacology and Toxicology from the University of the Sciences in Philadelphia (2012), Thomas Jefferson University (2006), and Philadelphia College of Pharmacy and Science (1996), respectively and is a Fellow in the Royal Society of Biology. She is a Scientific Leader and Fellow at GlaxoSmithKline (GSK) within the In vitro/In vivo Translation and Investigative Transcriptional and Cellular Safety Department where she conducts and oversees state of the art genomic and proteomic investigations to elucidate mechanisms of toxicity observed in nonclinical species and humans, develops in vitro predictive toxicological assays and biomarkers of toxicity and has a research focus on drug-induced vascular injury (DIVI). Dr. Dalmas has pioneered the development of predictive mRNA biomarkers of drug induced vascular injury and use of formalin-fixed paraffin-embedded tissue for retrospective investigations into mechanisms of toxicity. In addition, she currently oversees development of various GSK assets aimed at altering epigenetic mechanisms from early target selection through to Regulatory approval. Dr. Dalmas is currently an active member and Co-Chair of the Critical Path Institute Predictive Testing Consortium DIVI Working Group where she serves as the leader of the Study Design and Assay Development Subteams. In addition, she is also a member of the ILSI/HESI Genomic Committee where she serves on the FFPE Demodification for RNASeq and Zebrafish Transgenerational Assay Development Working Groups and is also an active member of the IQ DruSafe Mechanistic Toxicology as well as the Translation Biomarker Working Groups. She is the author/co-author of multiple peer-reviewed articles and has presented more than 30 abstract/poster presentations and numerous oral presentations at both national and international meetings, many on the topic of DIVI. In addition, she is also an ad hoc reviewer for various peer-reviewed journals including Toxicologic Pathology, Toxicology and Applied Pharmacology, and Toxicological Sciences.

Dr. Dalmas research interests are include Drug Induced Vascular Injury, Mechanistic Toxicology, Epigenetics, Cardiovascular Toxicity, and Biomarker Development